While MX69 treatment reduced viability in all MM cell lines, drug-resistant MM cells also showed a hyperbolic dose-response curve and have a two-to-five-fold higher IC50 than their parental drug-sensitive cells, in line with their higher MDM2 basal levels (Figure 3A, Supplementary Figure S3B). Here, MDM2 is linked to Miyoshi myopathy.